drugset / Trial / NCT06710990

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

NCT06710990

Phase 1 Completed 17 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.

Timeline

Start
2025-02-17
Primary completion
2025-10-15
Completion
2025-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule
Subject Ritonavir Other / unclassified
Subject Trastuzumab Rezetecan Monoclonal antibody

Indications